Overview
Phage display host strains are genetically engineered Escherichia coli derivatives specifically optimized for bacteriophage propagation and surface protein display. These strains form the biological foundation of phage display technology, which was first developed in 1985 by George P. Smith. The most common variants include TG1, XL1-Blue, and ER2738, each with distinct genetic modifications to enhance phage infection efficiency and protein expression. These strains typically carry the F' episome encoding pili for M13 phage attachment, along with selectable markers like tetracycline resistance. They may also contain suppressor tRNA genes (e.g., supE) to read through amber stop codons in phage display vectors. The choice of strain significantly impacts library diversity and display efficiency in applications ranging from antibody discovery to protein engineering.
Physical and Chemical Properties
As living bacterial systems, phage display strains don't conform to traditional chemical property metrics. Their performance is characterized by biological parameters: transformation efficiency (typically 10^7-10^9 CFU/μg DNA), doubling time (20-30 minutes in LB medium at 37°C), and phage production yield (10^10-10^12 pfu/mL). The strains are supplied either as glycerol stocks (viable at -80°C) or lyophilized cultures, requiring standard microbiological handling. Key functional properties include stable maintenance of the F' episome (essential for phage infection), absence of restriction systems that might degrade phage DNA, and optimized metabolic pathways for phage assembly. Some strains feature temperature-sensitive plasmid replication systems or inducible promoter elements for controlled phage production. Physical stability varies by formulation, with lyophilized strains typically stable for 1-2 years at -20°C when properly sealed.
Main Applications
In biopharmaceutical development, these strains enable construction of antibody fragment (scFv, Fab) libraries for therapeutic discovery. Over 80% of phage-derived antibodies in clinical trials originate from libraries displayed on E. coli strains like XL1-Blue. The technology also facilitates epitope mapping by displaying target protein fragments to identify antibody binding sites. Beyond antibodies, the strains support peptide library screening for drug discovery, with applications in oncology (targeting tumor receptors) and infectious diseases (blocking viral entry). In basic research, they're used to study protein-protein interactions through surface display of binding domains. Emerging applications include nanomaterials development through display of inorganic-binding peptides and enzyme evolution via displayed mutant libraries.
Safety and Storage
Standard BSL-1 precautions apply: use personal protective equipment (lab coat, gloves) and disinfect work surfaces with 70% ethanol. Though non-pathogenic, some strains carry antibiotic resistance genes requiring containment per local regulations. Avoid aerosol generation during centrifugation of phage cultures. For long-term storage, maintain master stocks at -80°C in 15-25% glycerol. Working stocks can be kept at -80°C for 1-2 years or at -20°C for 6 months. Lyophilized cultures remain stable for 2+ years when stored desiccated at -20°C. Revive strains on selective media (e.g., LB + tetracycline for XL1-Blue) and avoid excessive subculturing to prevent genetic drift. Quality control should include periodic checks of transformation efficiency and phage production capability.
B2B Procurement Guide
When sourcing phage display strains, verify genotype compatibility with your display vector system. Common requirements include: F' status (for M13 phage infection), suppressor tRNA genes (e.g., supE for amber suppression), and absence of competing restriction systems. Leading suppliers include Agilent Technologies (formerly Stratagene), New England Biolabs, and Thermo Fisher Scientific. Request certificates of analysis documenting strain pedigree, genotype verification, and performance metrics (transformation efficiency, phage yield). Bulk purchasing (5-10 strains) can reduce costs by 15-20%. For GMP applications, seek suppliers offering fully documented master cell banks. Consider ordering companion products like optimized growth media and phage precipitation solutions to streamline workflows. Lead times typically range from 1-3 weeks for standard strains.
Related Manufacturers
- 主营：染色液、感受态、滴定法、试剂盒、鸡血清、保存液、赖氨酸、脯氨酸、抗凝牛、猫血清、苏木素、巴氏法、缬氨酸、乙酸锂、类器官、青霉素、无酚红、苏氨酸、添加剂、色氨酸、酪氨酸、pbs干粉、噻唑蓝、硫酸镁、鲑鱼精
- 主营：科研试剂、高效试剂
- 主营：标准菌株、食用菌、微生物菌种、益生菌